$INSM News

BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript

Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning

Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reduction, And No Newly Identified Safety Signals In PAH

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161

Guggenheim Reiterates Buy on Insmed, Maintains $207 Price Target

Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)

Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)

EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors?

Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise?

Evercore ISI Group Maintains Outperform on Insmed, Lowers Price Target to $160

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Is Insmed (INSM) The Best Healthcare Stock to Buy Now?

JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $179

Is Insmed's (INSM) Brensocatib Momentum Quietly Reframing Its Respiratory Growth Narrative?

Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says

RBC Capital Maintains Outperform on Insmed, Lowers Price Target to $195